Page 336 - Clinical Immunology_ Principles and Practice ( PDFDrive )

316 Part two Host Defense Mechanisms and Inflammation

3. Walport MJ. Complement. First of two parts. N Engl J Med 30. Inal JM, Hui KM, Miot S, et al. Complement C2 receptor inhibitor
2001;344:1058–66. trispanning: a novel human complement inhibitory receptor. J Immunol
4. Walport MJ. Complement. Second of two parts. N Engl J Med 2005;174:356–66.
2001;344:1140–4. 31. Bohlson SS, Fraser DA, Tenner AJ. Complement proteins C1q and
5. Marnell L, Mold C, Du Clos TW. C–reactive protein: Ligands, receptors MBL are pattern recognition molecules that signal immediate and
and role in inflammation. Clin Immunol 2005;117:104–11. long–term protective immune functions. Mol Immunol 2007;44:
6. Kang YS, Do Y, Lee HK, et al. A dominant complement fixation pathway 33–43.
for pneumococcal polysaccharides initiated by SIGN–R1 interacting with 32. Liszewski MK, Atkinson JP. Membrane cofactor protein (MCP; CD46).
C1q. Cell 2006;125:47–58. Isoforms differ in protection against the classical pathway of complement.
7. Sorensen R, Thiel S, Jensenius JC. Mannan-binding-lectin-associated J Immunol 1996;156:4415–21.
serine proteases, characteristics and disease associations. Springer Semin 33. Roozendaal R, Carroll MC. Complement receptors CD21 and CD35 in
Immunopathol 2005;27:299–319. humoral immunity. Immunol Rev 2007;219:157–66.
8. Lachmann PJ. The amplification loop of the complement pathways. Adv 34. Holers VM. Complement and its receptors: new insights into human
Immunol 2009;104:115–49. disease. Annu Rev Immunol 2014;32:433–59.
9. Zewde N, Gorham RD Jr, Dorado A, et al. Quantitative Modeling of the 35. van Lookeren Campagne M, Wiesmann C, Brown EJ. Macrophage
Alternative Pathway of the Complement System. PLoS ONE complement receptors and pathogen clearance. Cell Microbiol
2016;11:e0152337. 2007;9:2095–102.
10. Janssen BJ, Christodoulidou A, McCarthy A, et al. Structure of C3b 36. Helmy KY, Katschke KJ Jr, Gorgani NN, et al. CRIg: a macrophage
reveals conformational changes that underlie complement activity. Nature complement receptor required for phagocytosis of circulating pathogens.
2006;444:213–16. Cell 2006;124:915–27.
11. Wiesmann C, Katschke KJ, Yin J, et al. Structure of C3b in complex with 37. Huber–Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the
CRIg gives insights into regulation of complement activation. Nature absence of C3: a new complement activation pathway. Nat Med
2006;444:217–20. 2006;12:682–7.
12. Forneris F, Wu J, Xue X, et al. Regulators of complement activity mediate 38. Klos A, Tenner AJ, Johswich KO, et al. The role of the anaphylatoxins in
inhibitory mechanisms through a common C3b-binding mode. EMBO J health and disease. Mol Immunol 2009;46:2753–66.
2016;35:1133–49. 39. Ward PA. Functions of C5a receptors. J Mol Med 2009;87:375–8.
13. Gaboriaud C, Juanhuix J, Gruez A, et al. The crystal structure of the 40. Gerard NP, Lu B, Liu P, et al. An anti-inflammatory function for the
globular head of complement protein C1q provides a basis for its versatile complement anaphylatoxin C5a-binding protein, C5L2. J Biol Chem
recognition properties. J Biol Chem 2003;278:46974–82. 2005;280:39677–80.
14. Gaboriaud C, Thielens NM, Gregory LA, et al. Structure and activation of 41. Rittirsch D, Flierl MA, Nadeau BA, et al. Functional roles for C5a
the C1 complex of complement: unraveling the puzzle. Trends Immunol receptors in sepsis. Nat Med 2008;14:551–7.
2004;25:368–73. 42. Ojha H, Panwar HS, Gorham RD Jr, et al. Viral regulators of complement
15. Dodds AW, Ren XD, Willis AC, et al. The reaction mechanism of the activation: structure, function and evolution. Mol Immunol
internal thioester in the human complement component C4. Nature 2014;61:89–99.
1996;379:177. 43. Yu Q, Yu R, Qin X. The good and evil of complement activation in
16. Matsushita M. Ficolins: complement-activating lectins involved in innate HIV–1 infection. Cell Mol Immunol 2010;7:334–40.
immunity. J Innate Immun 2010;2:24–32. 44. Holers VM, Kulik L. Complement receptor 2, natural antibodies and
17. Takahashi M, Ishida Y, Iwaki D, et al. Essential role of mannose-binding innate immunity: Inter-relationships in B cell selection and activation.
lectin-associated serine protease-1 in activation of the complement factor Mol Immunol 2007;44:64–72.
D. J Exp Med 2010;207:29–37. 45. Kopf M, Abel B, Gallimore A, et al. Complement component C3
18. Kemper C, Atkinson JP, Hourcade DE. Properdin: emerging roles of a promotes T-cell priming and lung migration to control acute influenza
pattern–recognition molecule. Annu Rev Immunol 2010;28:131–55. virus infection. Nat Med 2002;8:373–8.
+
19. Agarwal S, Ferreira VP, Cortes C, et al. An evaluation of the role of 46. Kemper C, Chan AC, Green JM, et al. Activation of human CD4 cells
properdin in alternative pathway activation on Neisseria meningitidis and with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature
Neisseria gonorrhoeae. J Immunol 2010;185:507–16. 2003;421:388–92.
20. Bubeck D. The making of a macromolecular machine: assembly of the 47. Hawlisch H, Kohl J. Complement and Toll–like receptors: key
membrane attack complex. Biochemistry Mosc 2014;53:1908–15. regulators of adaptive immune responses. Mol Immunol 2006;43:
21. Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human 13–21.
pathogens. Nat Rev Microbiol 2008;6:132–42. 48. Thurman JM, Holers VM. The central role of the alternative complement
22. Cole DS, Morgan BP. Beyond lysis: how complement influences cell fate. pathway in human disease. J Immunol 2006;176:1305–10.
Clin Sci 2003;104:455–66. 49. Taylor PR, Carugati A, Fadok VA, et al. A hierarchical role for classical
23. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat pathway complement proteins in the clearance of apoptotic cells in vivo. J
Rev Immunol 2009;9:729–40. Exp Med 2000;7:359–66.
24. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 50. Poon IK, Hulett MD, Parish CR. Molecular mechanisms of late apoptotic/
2008;359:1027–36. necrotic cell clearance. Cell Death Differ 2010;17:381–97.
25. Liszewski MK, Farries TC, Lublin DM, et al. Control of the complement 51. Du Clos TW, Mold C. Pentraxins (CRP, SAP) in the process of
system. Adv Immunol 1996;61:201–83. complement activation and clearance of apoptotic bodies through
26. Giannakis E, Jokiranta TS, Male DA, et al. A common site within factor H Fcgamma receptors. Curr Opin Organ Transplant 2011;16:15–20.
SCR 7 responsible for binding heparin, C–reactive protein and 52. Fadok VA, Bratton DL, Henson PM. Phagocyte receptors for apoptotic
streptococcal M protein. Eur J Immunol 2003;33:962–9. cells: recognition, uptake, and consequences. J Clin Invest
27. Manuelian T, Hellwage J, Meri S, et al. Mutations in factor H reduce binding 2001;108:957–62.
affinity to C3b and heparin and surface attachment to endothelial cells in 53. Gershov D, Kim S, Brot N, et al. C-Reactive protein binds to apoptotic
hemolytic uremic syndrome. J Clin Invest 2003;111:1181–90. cells, protects the cells from assembly of the terminal complement
28. Morgan HP, Schmidt CQ, Guariento M, et al. Structural basis for components, and sustains an antiinflammatory innate immune response:
engagement by complement factor H of C3b on a self surface. Nat Struct implications for systemic autoimmunity.[erratum appears in J Exp Med
Mol Biol 2011;18:463–70. 2001;193:1439]. J Exp Med 2000;192:1353–64.
29. Kim DD, Song WC. Membrane complement regulatory proteins. Clin 54. Mold C, Gewurz H, D Clos TW. Regulation of complement activation by
Immunol 2006;118:127–36. C-reactive protein. Immunopharmacology 1999;42:23–30.